PPARGC1A and polycystic ovary syndrome: Further stratification using adult treatment panel III criteria for metabolic syndrome revealed that PCOS patients with one or more risk factors (59.43%) had higher PPARGC1A methylation and lower mtDNA content than those without risk factors (41.57%).